13 completed, 3 not yet recruiting, 3 unknown, 2 active not recruiting. 24 Phase 2, 8 Phase 1.
Follow ALS: new trials by email Literature Review of ALS trials Research Report on ALS
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of [11C]CPPC as a Clinical PET Radioligand Biomarker of Microglial Activation in ALS [11C]CPPC PET ligand - ALS | Phase 1 / Phase 2 | Not yet recruiting | Johns Hopkins University | 20 | 2026-11-01 | 2026-08-25 |
| The BANYAN Trial, an ALS MyMatch Trial Evaluating Safety, Biomarker Activity, and Microglial Activation of Nasal Foralumab Foralumab Nasal, Placebo - ALS (Amyotrophic Lateral Sclerosis), ALS - Amyotrophic Lateral Sclerosis | Phase 2 | Enrolling by invitation | Tiziana Life Sciences LTD | 44 | 2026-09-23 | 2026-10-28 |
| A Study to Evaluate the Safety, Efficacy, and Pharmacodynamics of PLL001 in ALS Patients PLL001 or placebo daily subcutaneous injections - Amyotrophic Lateral Sclerosis, ALS | Phase 1 / Phase 2 | Not yet recruiting | PLL TX AUSTRALIA PTY LTD | 153 | 2026-04-08 | 2026-03-19 |
| Kamlanoflast In Amyotrophic Lateral Sclerosis Kamlanoflast - ALS (Amyotrophic Lateral Sclerosis), ALS | Phase 1 / Phase 2 | Not yet recruiting | Inflammasome Therapeutics | 40 | 2026-02-01 | 2026-02-09 |
| Treatment Combining Riluzole and IFB-088 in Bulbar Amyotrophic Lateral Sclerosis (TRIALS Protocol) IFB-088 50mg/day, Placebo, Riluzole 100mg/day - Amyotrophic Lateral Sclerosis, ALS | Phase 2 | Completed | InFlectis BioScience | 51 | 2022-12-02 | 2025-10-10 |
| Adenosine 2A Receptor Antagonism and AIH in ALS Consume 20mg of istradefylline, Low Oxygen therapy, Placebo counterpart to the istradefylline drug - ALS | Phase 1 / Phase 2 | Active not recruiting | University of Florida | 40 | 2022-06-21 | 2026-03-27 |
| A Phase IIb, Multi-Center, Multinational, Double-Blind, Placebo-Controlled Study, With an Open Label Extension, to Evaluate Safety, Tolerability and Efficacy of PrimeC in Subjects With ALS PrimeC, Placebo - Amyotrophic Lateral Sclerosis, ALS | Phase 2 | Completed | NeuroSense Therapeutics Ltd. | 69 | 2022-05-31 | 2025-09-05 |
| Study of Safety, Tolerability, and Biological Activity of LAM-002A in C9ORF72-Associated Amyotrophic Lateral Sclerosis LAM-002A, Placebo - Amyotrophic Lateral Sclerosis, ALS | Phase 2 | Completed | IRulya Therapeutics Inc. | 15 | 2021-12-23 | 2026-09-29 |
| NF-κB Inhibition in Amyotrophic Lateral Sclerosis Withania somnifera, Placebo - ALS | Phase 2 | Unknown | Sunnybrook Health Sciences Centre | 75 | 2021-10-19 | 2022-06-06 |
| Pharmacokinetic and Pharmacodynamic Study of AMX0035 in Patients With ALS AMX0035 - ALS | Phase 1 / Phase 2 | Unknown | Amylyx Pharmaceuticals Inc. | 14 | 2021-08-05 | 2023-07-24 |
| Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) or Frontotemporal Dementia (FTD) WVE-004, Placebo - ALS, FTD | Phase 1 / Phase 2 | Terminated | Wave Life Sciences USA, Inc. | 35 | 2021-06-28 | 2023-10-23 |
| Open Label Study to Evaluate Ciprofloxacin/Celecoxib Combination in Patients With ALS Fixed dose combination Ciprofloxacin/Celecoxib - Amyotrophic Lateral Sclerosis, ALS | Phase 2 | Completed | NeuroSense Therapeutics Ltd. | 16 | 2019-11-25 | 2021-03-03 |
| A Pilot Trial of Triheptanoin for People With Amyotrophic Lateral Sclerosis (PALS) Triheptanoin - ALS | Phase 1 / Phase 2 | Completed | Richard Bedlack, M.D., Ph.D. | 15 | 2018-06-21 | 2019-12-24 |
| Safety and Efficacy of Ranolazine for the Treatment of Amyotrophic Lateral Sclerosis Ranolazine 500 MG, Ranolazine 1000 MG - ALS | Phase 2 | Completed | University of Kansas Medical Center | 14 | 2018-06-11 | 2024-12-09 |
| Open Label Extension Study of AMX0035 in Patients With ALS AMX0035 - Amyotrophic Lateral Sclerosis, ALS | Phase 2 | Completed | Amylyx Pharmaceuticals Inc. | 90 | 2018-03-29 | 2025-08-13 |
| Riluzole Oral Soluble Film Safety and Tolerability in Amyotrophic Lateral Sclerosis Riluzole Oral Soluble Film - ALS | Phase 2 | Withdrawn | Aquestive Therapeutics | 2018-03-01 | 2019-05-13 | |
| A Clinical Trial of Pimozide in Patients With Amyotrophic Lateral Sclerosis (ALS) Pimozide 2mg/day (current) or 4 mg/day (study initiation), Placebo Oral Tablet - ALS, Amyotrophic Lateral Sclerosis | Phase 2 | Unknown | University of Calgary | 100 | 2017-10-27 | 2020-05-28 |
| Intrathecal Autologous Adipose-derived Mesenchymal Stromal Cells for Amyotrophic Lateral Sclerosis (ALS) Autologous Adipose-derived Mesenchymal Stromal Cells - ALS, Amyotrophic Lateral Sclerosis | Phase 2 | Active not recruiting | Mayo Clinic | 75 | 2017-10-10 | 2026-03-09 |
| Perampanel for Sporadic Amyotrophic Lateral Sclerosis (ALS) Perampanel, placebo - ALS | Phase 2 | Completed | Tokyo Medical University | 66 | 2017-04-24 | 2021-01-15 |
| Effect of MD1003 in Amyotrophic Lateral Sclerosis MD1003, Placebo oral capsule - ALS, Amyotrophic Lateral Sclerosis | Phase 2 | Completed | MedDay Pharmaceuticals SA | 30 | 2016-06-29 | 2019-06-04 |
Showing 20 of 24. Sign in to see all of them.
Amyotrophic Lateral Sclerosis (17) · Motor Neuron Disease (6) · Neurodegenerative Diseases (2) · Frontotemporal Dementia With Motor Neuron Disease (1) · Hypoxia (1) · Nervous System Diseases (1) · Neuroinflammatory Diseases (1) · Neuromuscular Diseases (1) · Respiratory Aspiration (1)
Central Nervous System Diseases (17) · Metabolic Diseases (17) · Nutritional and Metabolic Diseases (17) · Proteostasis Deficiencies (17) · Spinal Cord Diseases (17) · TDP-43 Proteinopathies (17) · Nervous System Diseases (16) · Neuromuscular Diseases (16) · Neurodegenerative Diseases (15) · Motor Neuron Disease (11) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Inflammation (1) · Respiration Disorders (1) · Respiratory Tract Diseases (1)
sodium phenylbutyrate and taurursodiol (2) · 4-phenylbutyric acid (1) · Acetates (1) · Ashwagandha (1) · Biotin (1) · Butyrates (1) · Celecoxib (1) · Control Groups (1) · Insemination, Artificial, Homologous (1) · Lactic Acid (1) · Pimozide (1) · Propionates (1) · Ranolazine (1) · Riluzole (1) · Sodium Chloride (1)
Amylyx Pharmaceuticals Inc. (2) · NeuroSense Therapeutics Ltd. (2) · Aquestive Therapeutics (1) · Barrow Neurological Institute (1) · Corestemchemon, Inc. (1) · Dartmouth-Hitchcock Medical Center (1) · IRulya Therapeutics Inc. (1) · InFlectis BioScience (1) · Inflammasome Therapeutics (1) · Johns Hopkins University (1) · Mayo Clinic (1) · MedDay Pharmaceuticals SA (1) · PLL TX AUSTRALIA PTY LTD (1) · Richard Bedlack, M.D., Ph.D. (1) · Sunnybrook Health Sciences Centre (1)
United States (12) · Canada (5) · France (3) · Israel (3) · Italy (3) · Belgium (2) · Netherlands (2) · Australia (1) · Germany (1) · Hungary (1) · Ireland (1) · Japan (1) · New Zealand (1) · South Korea (1) · Spain (1)
Agessandro Abrahao, MD, MSc (1) · Anthony J Windebank, MD (1) · Barbara Smith (1) · Elijah Stommel (1) · Emily Plowman, PhD, CCC-SLP (1) · Giuseppe Lauria, Pr (1) · James Wymer, MD, PhD (1) · Jeffrey Statland, MD (1) · Lawrence Korngut, M.D. (1) · Lorne Zinman, MD, MSc (1) · Nathan P Staff, MD, PhD (1) · Nicholas Maragakis, MD (1) · Richard S Bedlack, MD PhD (1) · Sabrina Paganoni, MD, PhD (1)
PMID 25934946, PMID 30048006, PMID 32140672, PMID 33063909, PMID 34075589, PMID 35508892, PMID 35577511, PMID 38606777, PMID 41202295, PMID 41837970